Speedboat™ Inject selected by NICE for assessment

The National Institute for Health and Care Excellence (“NICE”) has selected Speedboat Inject to be scoped and routed for guidance in respect of the endoscopic submucosal dissection (“ESD”) of lower gastrointestinal (“GI”) lesions.

This selection follows a committee review of headline data and initiates a multi-step process whereby Speedboat’s lower GI ESD clinical and economic evidence, along with other data, is evaluated by NICE and, if appropriate, may result in a specific NICE output such as Medical Technologies Guidance.

NICE selected Speedboat Inject for scoping and routing because it “anticipate[s] the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources”.

More information on Speedboat’s guidance development can be found here.

Craig Gulliford, CEO of Creo Medical, said:

We are delighted that Speedboat Inject has reached this stage with NICE and the validation this provides given the progress we are already making in the UK. We look forward to the outcome of the final stages of the review process as NICE concludes its work.

Posted 06/01/23

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

19 March 2024

Welsh Labour Leader visits Creo’s facilities

Read

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi

Read

31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

Read

10 January 2024

First Use of Speedboat® UltraSlim in Latin America

Read

13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch

Read

01 November 2023

Speedboat® UltraSlim: US FDA Clearance

Read

25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months

Read

12 September 2023

Half Year Report: H1-2023

Read

19 June 2023

Speedboat Inject cleared for upper GI use in Europe

Read

23 May 2023

First in-human milestone reached for MicroBlate™ Flex as part of Lung Tissue ablation clinical study

Read